Sobrera is a clinical phase biopharma company developing new treatments for patients with addiction disorders
Sobrera is a Swedish biopharma company developing new treatments for patients with addiction disorders. It is based on research from the Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry at the Sahlgrenska Academy, University of Gothenburg. The inventors are Prof. Bo Söderpalm and Dr. Andrea de Bejczy. They have substantial experience of research in alcohol abuse and in managing clinical studies in Alcohol Use Disorder (AUD).
Our focus is on SO-001, a new therapy for Alcohol Use Disorder where there is a large unmet medical need. Alcohol Use Disorder is a major global health issue and a major cause of mortality and morbidity. Available treatments for Alcohol Use Disorder are moderately effective and improved treatments are much needed.
A clinical phase II randomized controlled trial is ongoing, examining the effects and safety of the new therapy in patients with moderate to severe Alcohol Use Disorder.
Our Mission and Value proposition
Together we generate highly effective and accessible treatments reducing the medical and social consequences of Alcohol Use Disorder.
To make everyday life better for patients suffering from addiction disorders and other mental conditions.